Qing Zhang

Qing Zhang

Auto-generated profile, based on publicly available information

Qing Zhang

Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2021 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
RCRanran Chen
Ranran Chen
YHYuanjian Huang
Yuanjian Huang
LWLu Wang
Lu Wang
JZJiahui Zhou
Jiahui Zhou
YTYuqian Tan
Yuqian Tan
YSYueming Sun
Yueming Sun
Antibody-functionalized targeted nanocarriers to deliver chemotherapeutics have been widely explored. However, it remains highly desirable to understand and apply the antitumor potential of antibodies integrated in hybrid composite nanoplatforms. Herein, mesoporous silica nanoparticles, a supported lipid bilayer and cetuximab were integrated to fabricate a hybrid nanoplatform for effectively encapsulating and selectively delivering 5-fluorouracil (5-FU) against colorectal cancer (CRC) cells. The specially designed nanoplatform exhibited superior properties, such as satisfying size distribution, dispersity and stability, drug encapsulation, controlled release, and cellular uptake. Interestingly, the modification of cetuximab onto nanoplatforms without drug loading can significantly inhibit the migration and invasion of CRC cells through suppressing the epidermal growth factor receptor (EGFR)-associated signaling pathway. Furthermore, delivery of 5-FU by using this nanoplatform can remarkably induce cytotoxicity, cell cycle arrest, and cell apoptosis for CRC cells with high EGFR expression. Overall, this nanostructured platform can dramatically improve the tumor killing effects of encapsulated chemotherapeutics and present antimigration effects derived from the antibody modified on it. Moreover, in vivo biodistribution experiments demonstrated the superior tumor targeting ability of the targeted nanoparticles. Thus, this targeted nanoplatform has substantial potential in combinational therapy of antibodies and chemotherapy agents against colorectal cancer.

9 June 2022 in Journal of Materials Science & Technology
Verified
Journal Article
Closed access
XHXiuping Han
Xiuping Han
WFWenyou Fang
Wenyou Fang
TZTianqi Zhang
Tianqi Zhang
XZXuan Zhong
Xuan Zhong
KQKun Qian
Kun Qian
QZQing Zhang
Qing Zhang

29 July 2024 in ACS Applied Nano Materials
Verified
Journal Article
Closed access
YDYin Dai
Yin Dai
XWXinyi Wen
Xinyi Wen
HFHuizhu Fan
Huizhu Fan
JHJunqiang Hong
Junqiang Hong
LHLuxi Huang
Luxi Huang
JHJunli Hong
Junli Hong

9 July 2022 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
NWNan Wang
Nan Wang
LSLiangyu Shao
Liangyu Shao
WLWenjie Lu
Wenjie Lu
WFWenyou Fang
Wenyou Fang
QZQing Zhang
Qing Zhang
RHRongfeng Hu
Rongfeng Hu

13 July 2023 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
LSLing Feng Sun
Ling Feng Sun
MLMan Man Li
Man Man Li
YCYuan Chen
Yuan Chen
WLWen Jie Lu
Wen Jie Lu
QZQing Zhang
Qing Zhang
RHRongfeng Hu
Rongfeng Hu

24 July 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
LWLujun Wang
Lujun Wang
BZBaolin Zhu
Baolin Zhu
WLWenjie Lu
Wenjie Lu
QZQing Zhang
Qing Zhang
WFWenyou Fang
Wenyou Fang
RHRongfeng Hu
Rongfeng Hu